BOLT BIOTHERAPEUTICS, INC.

(BOLT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/23/2022 05/24/2022 05/25/2022 05/26/2022 05/27/2022 Date
1.56(c) 1.6(c) 1.69(c) 1.75(c) 1.8(c) Last
103 532 244 870 217 528 134 399 120 687 Volume
-4.29% +2.56% +5.63% +3.55% +2.86% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 2,78 M - -
Net income 2022 -105 M - -
Net cash position 2022 144 M - -
P/E ratio 2022 -0,64x
Yield 2022 -
Sales 2023 2,75 M - -
Net income 2023 -124 M - -
Net cash position 2023 278 M - -
P/E ratio 2023 -0,63x
Yield 2023 -
Capitalization 67,4 M 67,4 M -
EV / Sales 2022 -27,7x
EV / Sales 2023 -76,6x
Nbr of Employees 91
Free-Float 93,1%
More Financials
Company
Bolt Biotherapeutics, Inc is a clinical-stage immuno-oncology company. The Company is focused on developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The Company’s products include BDC-1001, BDC-2034, BDC-3042 and PD-L1 Boltbody Immune-Stimulating Antibody Conjugate (ISAC). The Company’s lead product candidate, BDC-1001, is in clinical development for the... 
Sector
Biotechnology & Medical Research
Calendar
06/05 | 09:00amPresentation
More about the company
Ratings of Bolt Biotherapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about BOLT BIOTHERAPEUTICS, INC.
05/27Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape ..
GL
05/27Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape ..
GL
05/17Morgan Stanley Adjusts Bolt Biotherapeutics' Price Target to $5 from $7, Keeps Equalwei..
MT
05/16Stifel Adjusts Bolt Biotherapeutics' Price Target to $13 From $16, Reiterates Buy Ratin..
MT
05/12BOLT BIOTHERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
05/12Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
05/12Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business..
GL
05/12Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business..
GL
04/08BOLT BIOTHERAPEUTICS : CEA BDC-2034 AACR Poster
PU
04/08BOLT BIOTHERAPEUTICS : Dectin-2 AACR Poster
PU
04/08BOLT BIOTHERAPEUTICS : PD-L1 ISAC AACR Poster
PU
04/07Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conference
GL
03/31Bolt Biotherapeutics Files $250 Million Mixed Shelf
MT
03/30BOLT BIOTHERAPEUTICS : Reports Four Quarter and Full Year 2021 Financial Results and Provi..
PU
03/30BOLT BIOTHERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
More news
News in other languages on BOLT BIOTHERAPEUTICS, INC.
05/12Bolt Biotherapeutics, Inc. annonce ses résultats pour le premier trimestre se terminant..
03/30Bolt Biotherapeutics, Inc. annonce ses résultats pour le quatrième trimestre clos le 31..
03/30Bolt Biotherapeutics, Inc. annonce ses résultats pour l'année complète se terminant le ..
03/04Bolt Biotherapeutics, Inc. annonce la démission de David Dornan en tant que directeur s..
01/06Bolt Biotherapeutics administre une dose au premier patient du volet combiné de l'essai..
More news
Analyst Recommendations on BOLT BIOTHERAPEUTICS, INC.
More recommendations
Chart BOLT BIOTHERAPEUTICS, INC.
Duration : Period :
Bolt Biotherapeutics, Inc. Technical Analysis Chart | BOLT | US0977021049 | MarketScreener
Technical analysis trends BOLT BIOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,80 $
Average target price 8,50 $
Spread / Average Target 372%
EPS Revisions
Managers and Directors
Randall C. Schatzman Chief Executive Officer & Director
William P. Quinn Chief Financial Officer
Edith A. Perez Chief Medical Officer
Mahendra G. Shah Independent Director
Edgar G. Engleman Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BOLT BIOTHERAPEUTICS, INC.-63.27%67
GILEAD SCIENCES, INC.-10.76%81 280
REGENERON PHARMACEUTICALS, INC.9.70%74 647
VERTEX PHARMACEUTICALS24.65%70 008
BIONTECH SE-35.24%40 574
WUXI APPTEC CO., LTD.-22.01%39 958